1) c lupus erythematosus, and 0.10% Behcet's disease . |
2) and contribute to the development of this disease. |
3) tion and exacerbation of reactive airways disease. |
4) y presenting features, despite widespread disease. |
5) than 40 years to rule out coronary artery disease. |
6) erosclerosis, diabetes, or chronic kidney disease. |
7) any saw atherosclerosis as a lipid-driven disease. |
8) ry nodules throughout the course of their disease. |
9) ation often crucial for identification of disease. |
10) second cause of chronic obstructive lung disease. |
11) ultiple sclerosis, and inflammatory bowel disease. |
12) at IL-1 plays a pathological role in this disease. |
13) al dysplasia resembling lysosomal storage disease. |
14) s D exhibited a protective effect in this disease. |
15) tiation for patients with end-stage renal disease. |
16) ed for effective treatment of Parkinson's disease. |
17) hat are currently being evaluated for the disease. |
18) heart failure, stroke, and endstage renal disease. |
19) the treatment of sarcoid associated renal disease. |
20) proved to be responsible for this muscle disease. |
21) n consequence of rapid progression of the disease. |
22) is a modifiable risk factor for metabolic disease. |
23) s appeared as a significant factor in the disease. |
24) ealth among patients with cardiopulmonary disease. |
25) cted on 1003 patients with cardiovascular disease. |
26) t for patients' ability to manage chronic disease. |
27) s positive effect on the prognosis of the disease. |
28) s themselves often provoke acute vascular disease. |
29) h potential for cellular therapy of liver disease. |
30) ic acid (TNBS)-induced inflammatory bowel disease. |
31) cations of atherosclerotic cardiovascular disease. |
32) ain was 2 times higher in patients with a disease. |
33) ay represent a therapeutic target in this disease. |
|